Evidence map›Paper›PMID 41158701›Full record

ArticleMolecular and clinical oncology2025

Current status and issues regarding genetic medicine after cancer gene panel testing in Japanese patients with metastatic prostate cancer.

Hideyasu Tsumura, Dai Koguchi, Ken-Ichi Tabata, Soichiro Shimura, Shuhei Hirano, Takefumi Satoh, Keiko Takahashi, Naomi Araki, Rika Kawata, Akinori Watanabe and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hideyasu TsumuraDepartment of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Dai KoguchiDepartment of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Ken-Ichi TabataDepartment of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Soichiro ShimuraDepartment of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Shuhei HiranoDepartment of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Takefumi SatohDepartment of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Keiko TakahashiDivision of Genetics, Department of Genetics, Kitasato University Hospital, Sagamihara, Kanagawa 252-0375, Japan.
Naomi ArakiDivision of Genetics, Department of Genetics, Kitasato University Hospital, Sagamihara, Kanagawa 252-0375, Japan.
Rika KawataDivision of Genetics, Department of Genetics, Kitasato University Hospital, Sagamihara, Kanagawa 252-0375, Japan.
Akinori WatanabeDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Tsutomu YoshidaDivision of Molecular Pathology, Department of Comprehensive Medicine, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Jiichiro SasakiDepartment of Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.
Fumio TakadaDivision of Genetics, Department of Genetics, Kitasato University Hospital, Sagamihara, Kanagawa 252-0375, Japan.
Kazumasa MatsumotoDepartment of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study investigated the current status and issues regarding publicly reimbursed comprehensive genomic profiling (CGP) tests in Japan, as well as the implementation status of genetic counseling for cancer susceptibility genes identified by tumor-only sequencing in patients with prostate cancer. The data of 86 patients with metastatic prostate cancer who underwent CGP tests at a single institution between August 2019 and November 2024 were reviewed using either FoundationOne

Indexed as

comprehensive genomic profilinggenetic counselinggenetic testinggenotype-matched therapyhereditary cancerprostate cancersecondary findings

Identifiers

PMID41158701
PMCPMC12557695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.